- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03927690
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
A Randomized, Active-controlled, Patient and Investigator-masked, Multiple Dose Proof-of-concept Study of Intravitreal LKA651 in Patients With Diabetic Macular Edema
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 13353
- Novartis Investigative Site
-
Gottingen, Germany, 37075
- Novartis Investigative Site
-
Hannover, Germany, 30625
- Novartis Investigative Site
-
Muenster, Germany, 48145
- Novartis Investigative Site
-
Tuebingen, Germany, 72076
- Novartis Investigative Site
-
-
-
-
-
Arecibo, Puerto Rico, 00612
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spain, 08025
- Novartis Investigative Site
-
Cordoba, Spain, 14012
- Novartis Investigative Site
-
Zaragoza, Spain, 50009
- Novartis Investigative Site
-
-
Andalucia
-
Sevilla, Andalucia, Spain, 41009
- Novartis Investigative Site
-
-
Catalunya
-
Sant Cugat, Catalunya, Spain, 08190
- Novartis Investigative Site
-
-
-
-
-
Ankara, Turkey, 06100
- Novartis Investigative Site
-
Ankara, Turkey, 06500
- Novartis Investigative Site
-
Ankara, Turkey, 06490
- Novartis Investigative Site
-
Kocaeli, Turkey, 41380
- Novartis Investigative Site
-
-
-
-
California
-
Beverly Hills, California, United States, 90211
- Novartis Investigative Site
-
Rancho Cordova, California, United States, 95670
- Novartis Investigative Site
-
-
Florida
-
Miami, Florida, United States, 33143
- Novartis Investigative Site
-
-
Hawaii
-
'Aiea, Hawaii, United States, 96701
- Novartis Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Novartis Investigative Site
-
-
Texas
-
Austin, Texas, United States, 78750
- Novartis Investigative Site
-
San Antonio, Texas, United States, 78240
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Written informed consent must be obtained before any assessment is performed.
- Male and female patients age 18 to 85 years of age inclusive at screening
- Presence of type I or type II diabetes mellitus
- The Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye must be between 24 and 70 letters (approximate Snellen equivalent of 20/40-20/320). The non-study eye (fellow eye) should be ≥34 letters or better (approximate Snellen equivalent of 20/200) at screening
- Presence of Diabetic macular edema (DME) in the study eye, with decrease in vision due to foveal thickening of central macular thickness ≥ 320 µm in the central subfield, as assessed on Spectral domain optical coherence tomography (SD-OCT) and confirmed by the central reading center at screening
- Sufficiently clear ocular media and adequate pupil dilation in the study eye to permit fundus photographs of adequate clarity to measure diameters of retinal arteries and veins at screening
Exclusion criteria
- Patient with history of intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) treatment in the study eye <90 days from baseline
- Patient with history of intraocular corticosteroids including dexamethasone intravitreal implants during the 6 month period prior to baseline. Any prior use of fluocinolone acetonide intravitreal implant (Iluvien) is prohibited regardless of timing
- Laser photocoagulation (macular or panretinal) in the study eye during the 3-month period prior to baseline.
- High risk proliferative diabetic retinopathy
- Patients, with type 1 or type 2 diabetes who have a hemoglobin A1C ≥ 12% at screening.
- Any progressive disease of the retina in the study eye (e.g. uveitis,rod-cone dystrophy) or optic nerve
- Area of macular retinal ischemia (as measured by the foveal avascular zone) ≥ 1000 μm.
- Active intraocular inflammation (graded as trace or above) or active intraocular infection in either eye.
- Current diagnosis of or laboratory evidence for anemia, defined as a hemoglobin <10 g/dL for women and <11 g/dL for men.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LKA651
LKA651 Intravitreal injection
|
LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
|
Experimental: LKA651 + Lucentis
LKA651 + Lucentis Intravitreal injection
|
LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
|
Active Comparator: Lucentis
Lucentis Intravitreal injection
|
Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events
Time Frame: Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
|
An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or clinical investigation patient. The severity of the AEs (mild, moderate, severe) was based on the Common Terminology Criteria for Adverse Events (CTCAE). Number of participants in each category is reported in the table. A participant who falls multiple times in one category is counted only once. |
Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
|
Number of Participants With Ocular Adverse Events by Preferred Term in Study Eye
Time Frame: Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
|
An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or clinical investigation patient.
|
Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
|
Number of Participants With Non-ocular Adverse Events (>=2%)
Time Frame: Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
|
An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or clinical investigation patient.
|
Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
|
Intraocular Pressure (IOP) in Study Eye
Time Frame: Screening, and Day 85
|
Intraocular pressure was measured per the study site's regular practice.
|
Screening, and Day 85
|
Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Charts in Study Eye
Time Frame: Days 2, 8, 15, 29, 43, 57, and 85
|
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Visual function of the study eye was assessed using the ETDRS protocol. BCVA in study eye was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Baseline BCVA value and treatment naïve and treatment experienced variable were used as covariates. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning. |
Days 2, 8, 15, 29, 43, 57, and 85
|
Inner Macular Thickness (Inferior)
Time Frame: Week 12 (Day 85)
|
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
|
Week 12 (Day 85)
|
Inner Macular Thickness (Temporal)
Time Frame: Week 12 (Day 85)
|
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
|
Week 12 (Day 85)
|
Outer Macular Thickness (Inferior)
Time Frame: Week 12 (Day 85)
|
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
|
Week 12 (Day 85)
|
Outer Macular Thickness (Temporal)
Time Frame: Week 12 (Day 85)
|
Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).
|
Week 12 (Day 85)
|
Number of Participants Without Changes in Foveal Avascular Zone as Measured by Fluorescein Angiography (FA) in Study Eye
Time Frame: Days 29, 57, 85, End of Study (Up to Day 140)
|
Foveal avascular zone was assessed by fluorescein angiography (FA).
|
Days 29, 57, 85, End of Study (Up to Day 140)
|
Mixed Model Repeated Measures Analysis of Ratio to Baseline in Central Subfield Retinal Thickness (CSFT) in the Study Eye
Time Frame: Days 8, 15, 29, 43, 57, 85
|
Central subfield thickness was measured by spectral domain optical coherence tomography (SD-OCT).
Central subfield retinal thickness was analyzed with a mixed model for repeated measures.
The model included treatment, visit, and the treatment by visit interaction as independent variables.
An unstructured residual covariance structure was used.
Log-transformed baseline central subfield retinal thickness and treatment naïve and treatment experienced variable were used as covariates.
Results were back-transformed to show results as a ratio to baseline.
|
Days 8, 15, 29, 43, 57, 85
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Needed Retreatment With Anti-VEGF in Study Eye After Week 12
Time Frame: Week 12 (Day 85) up to Day 140
|
Week 12 (Day 85) up to Day 140
|
|
Time to Retreatment in Study Eye With Anti-VEGF After Week 12
Time Frame: Week 12 (Day 85) up to Day 140
|
Time to retreatment with anti VEGF (as determined by the investigator) after Week 12 during the additional 12 week extension phase (that was up to 16 weeks after the last dose) was examined with a Kaplan Meier plot.
|
Week 12 (Day 85) up to Day 140
|
Summary Statistics of Pharmacokinetics - Serum Concentrations of LKA651
Time Frame: Day 1 (0, 0.5 and 4 hrs post dose), Day 2, Day 8, Day 15, Day 29 (0, 0.5 and 4 hrs post dose), Day 43, Day 57 (0, 0.5 and 4 hrs post dose), Day 85
|
PK parameters were determined using non-compartmental methods using the most recent version of WinNonlin Phoenix (Version 8.2). Concentrations below the lower limit of quantification (LLOQ) were treated as 1/2 LLOQ in summary statistics. |
Day 1 (0, 0.5 and 4 hrs post dose), Day 2, Day 8, Day 15, Day 29 (0, 0.5 and 4 hrs post dose), Day 43, Day 57 (0, 0.5 and 4 hrs post dose), Day 85
|
Summary Statistics of Pharmacokinetics - AUC0-28d of LKA651 (Serum)
Time Frame: Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85
|
Area under the curve over the dosing interval 0 to 28 days.
|
Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85
|
Summary Statistics of Pharmacokinetics - Serum Concentrations of Lucentis
Time Frame: Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85
|
Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85
|
|
Summary Statistics of Pharmacokinetics - AUC0-28d of Lucentis (Serum)
Time Frame: Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85
|
Area under the curve over the dosing interval 0 to 28 days.
|
Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- diabetic macular edema
- macular edema
- AMD
- Lucentis
- Macular degeneration
- neovascular age-related macular degeneration
- diabetic retinopathy
- vision loss
- retinal vein occlusion
- RVO
- DME
- wet macular degeneration
- age-related macular degeneration (ARMD)
- macula damage
- retina damage
- dry macular degeneration
- nAMD
- Diabetic Macular edema (DME)
- LKA651
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLKA651X2202
- 2018-000031-28 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on LKA651
-
Novartis PharmaceuticalsCompletedDiabetic Macular Edema | Macular Edema | Neovascular Age-related Macular Degeneration | Retinal Vein OcclusionsPuerto Rico, United States
-
Alcon ResearchNovartis Institutes for BioMedical ResearchWithdrawn